Baillie Gifford & CO Blueprint Medicines Corp Transaction History

Baillie Gifford & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 20, 2022	SELL	$94.25 - $115.99 $2,639 - $3,247	-28 Reduced 8.16%	315 $34,000
Q3 2021 Oct 19, 2021	SELL	$80.98 - $109.47 $4,939 - $6,677	-61 Reduced 15.1%	343 $35,000
Q2 2021 Aug 02, 2021	SELL	$82.78 - $101.0 $1,821 - $2,222	-22 Reduced 5.16%	404 $36,000
Q1 2021 May 06, 2021	BUY	$90.71 - $108.28 $38,642 - $46,127	426 New	426 $41,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

Stay updated on Baillie Gifford & CO with notifications on news.